Inovio Pharmaceuticals, Inc. (AMEX:INO) entered into an office lease (the “Lease”) with a publicly owned real estate investment trust, located in Plymouth Meeting, Pennsylvania. We expect to occupy the space commencing in the third quarter of 2014. The initial term of the lease is eleven and one-half years. We intend to use the facility for office purposes. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was 3.53% in last session and finished the day at $3.52. Traded volume was 7,326,080 million shares in the last session and the average volume of the stock remained 7.12 million shares. The beta of the stock remained 3.70. Inovio Pharmaceuticals Inc (NYSEMKT:INO) insider ownership is 0.30%.

Northwest Biotherapeutics (NASDAQ:NWBO) is today’s next winner, up 29% today after some good news coming out of Europe for the company’s brain cancer vaccine DCVax-L. German hospitals are allowed to give the drug to patients with any type of glioma brain cancer, whether they are newly diagnosed or recurrent, under the compassionate use standard. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) rose 29.55 percent to $7.85 yesterday on volume of 6.18 million shares. The intra-day range of the stock was $6.36 to $8.25. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) has a market capitalization of $340.76million.

Peregrine Pharmaceuticals (NASDAQ:PPHM) on Mar. 7 announced financial results for the third quarter of fiscal year (FY) 2014 ended January 31, 2014 and provided an update on its advancing clinical pipeline and other corporate developments. Total revenues for the third quarter of FY 2014 were $3,885,000, compared to $7,039,000 for the same quarter of the prior fiscal year. Peregrine Pharmaceuticals (NASDAQ:PPHM)’s stock on Mar 10, 2014 reported closing price of $2.40. Its fifty two weeks range is $1.11 -$3.18. The total market capitalization recorded $384.79 million. The overall volume in the last trading session was 5,937,653 million shares. In its share capital, Peregrine Pharmaceuticals (NASDAQ:PPHM) has 156.95 million outstanding shares.

Analysts at MLV & Co. reiterated a “buy” rating on shares of MannKind Corporation (NASDAQ:MNKD) in a research note on Thursday, February 20th. On Monday, shares of MannKind Corporation (NASDAQ:MNKD) close the day at $5.71. Company’s monthly performance is recorded as 11.74%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 14.89%.